66 episodes

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerVoice Heart & Lung Audio PeerVoice

    • Science
    • 5.0 • 1 Rating

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    Best Practices in Early-Stage EGFR-Mutant NSCLC: A Primer for Radiation Oncologists

    Best Practices in Early-Stage EGFR-Mutant NSCLC: A Primer for Radiation Oncologists

    Visit https://www.peervoice.com/CHA860 to view the entire programme with slides. After completing “Best Practices in Early-Stage EGFR-Mutant NSCLC: A Primer for Radiation Oncologists”, participants will be able to: Discuss recent clinical data on the management of early-stage EGFR-mutant NSCLC; Explain best practices for mutational testing in patients with early-stage EGFR-mutant NSCLC; Develop strategies to improve communication and collaboration among the multidisciplinary team.

    • 18 min
    Improving Outcomes in Localised EGFR-Mutant NSCLC: Perspectives for Pulmonologists

    Improving Outcomes in Localised EGFR-Mutant NSCLC: Perspectives for Pulmonologists

    Visit https://www.peervoice.com/VDG860 to view the entire programme with slides. After completing “Improving Outcomes in Localised EGFR-Mutant NSCLC: Perspectives for Pulmonologists”, participants will be able to: Discuss recent clinical data on the management of localised EGFR-mutant NSCLC; Explain best practices for mutational testing in patients with localised EGFR-mutant NSCLC; Develop strategies to improve communication and collaboration among the multidisciplinary team.

    • 26 min
    "Setting New Goals for Slowing Progression in Chronic Kidney Disease: What Is Possible With GLP-1 RAs?"

    "Setting New Goals for Slowing Progression in Chronic Kidney Disease: What Is Possible With GLP-1 RAs?"

    Visit https://www.peervoice.com/FEW860 to view the entire programme with slides. After completing “Setting New Goals for Slowing Progression in Chronic Kidney Disease: What Is Possible With GLP-1 RAs?”, participants will be able to: Explain the rationale for the current focus on slowing the progression of chronic kidney disease (CKD) in patients with type 2 diabetes (T2DM); Evaluate the use of GLP-1 RAs as part of a for multifactorial management plan for patients with T2DM and CKD; Formulate treatment plans incorporating current guideline recommendations to slow the progression of CKD in patients with T2DM.

    • 39 min
    Understanding Hypercapnia in Adult Respiratory Distress Syndrome: The Quest for Optimal Patient Outcomes

    Understanding Hypercapnia in Adult Respiratory Distress Syndrome: The Quest for Optimal Patient Outcomes

    Visit https://www.peervoice.com/PTD860 to view the entire programme with slides. After completing “Understanding Hypercapnia in Adult Respiratory Distress Syndrome: The Quest for Optimal Patient Outcomes”, participants will be able to: Explain the impact of hypercapnia on critically ill patients within the intensive care setting; Identify patients who would be candidates for low-flow extracorporeal carbon dioxide removal (ECCO2R); Evaluate how to appropriately integrate low-flow ECCO2R techniques in clinical practice.

    • 12 min
    GnRH Antagonist vs LHRH Agonist: To Desensitize or To Inhibit, That Is the Question!

    GnRH Antagonist vs LHRH Agonist: To Desensitize or To Inhibit, That Is the Question!

    Visit https://www.peervoice.com/FKG860 to view the entire programme with slides. After completing “GnRH Antagonist vs LHRH Agonist: To Desensitize or To Inhibit, That Is the Question!”, participants will be able to: Differentiate between GnRH antagonists and LHRH agonists; Describe the recent clinical trial data assessing GnRH antagonist therapy for the treatment of prostate cancer; Discuss if GnRH antagonist therapy may lead to different clinical outcomes.

    • 19 min
    Stroke Prevention, Type 2 Diabetes, and GLP-1 Receptor Agonists: What Neurologists Need to Know

    Stroke Prevention, Type 2 Diabetes, and GLP-1 Receptor Agonists: What Neurologists Need to Know

    Visit https://www.peervoice.com/UWX860 to view the entire programme with slides. After completing “Stroke Prevention, Type 2 Diabetes, and GLP-1 Receptor Agonists: What Neurologists Need to Know”, participants will be able to: Explain the role of GLP-1 RAs in stroke prevention in type 2 diabetes (T2DM); Evaluate the cardiovascular outcomes data for GLP-1 RAs in terms of stroke prevention in patients with T2DM; and Apply optimal treatment plans for reducing the risk of stroke in patients with T2DM.

    • 44 min

Customer Reviews

5.0 out of 5
1 Rating

1 Rating

Top Podcasts In Science

Listeners Also Subscribed To

More by PeerVoice